Pituitary tumor size in acromegaly during pegvisomant treatment: Experience from MR re-evaluations of the German Pegvisomant Observational Study

European Journal of Endocrinology

Volumn 161, Issue 1, 2009, Pages 27-35

  Buchfelder, Michael ^g   Weigel, D ^g   Droste, M ^a   Mann, K ^b   Saller, B ^c   Brubach K ^c   Stalla, G K ^d   Bidlingmaier, M ^e   Strasburger, C J ^f  

^a Endocrine Practice   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; LONG ACTING DRUG; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; DRUG DERIVATIVE; HUMAN GROWTH HORMONE;

ACROMEGALY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE SURGERY; FEMALE; FOLLOW UP; GERMANY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; BLOOD; CLINICAL TRIAL; FACTUAL DATABASE; HYPOPHYSIS TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

ACROMEGALY; ADULT; AGED; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMAN GROWTH HORMONE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RISK FACTORS;

EID: 67650761129     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0910     Document Type: Article

References (27)

1. Melmed S. Medical progress: acromegaly. New England Journal of Medicine 2006 355 2558-2573.
2. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA & Giustina A. Consensus statement: medical management of acromegaly. European Journal of Endocrinology 2005 153 737-740.
3. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennet WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177.
4. Van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
5. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B & Strasburger CJ. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology 2007 156 75-82.
6. Strasburger CJ, Buchfelder M, Droste M, Mann K, Stalla GK & Saller B. German Pegvisomant Investigators: experience from the German Pegvisomant Observational Study. Hormone Research 2007 68 70-73.
7. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC & Bennett WF. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. Journal of Clinical Endocrinology and Metabolism 1999 84 2098-2103.
8. Veldhuis JD, Bidlingmaier M, Anderson SM, Evans WS, Wu Z & Strasburger CJ. Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. Journal of Clinical Endocrinology and Metabolism 2002 87 5737-5745.
9. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ & Lombardi G. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF1 levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology 2006 154 467-477.
10. Daousi C, Foy PM & McFarlane IA. Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumors. Journal of Neurology, Neurosurgery, and Psychiatry 2007 78 93-95.
11. Buchfelder M, Fahlbusch R, Thierauf P & Müller OA. Observations on the pathophysiology of Nelson's syndrome. Neurosurgery 1990 27 961-968.
12. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ & Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Journal of Clinical Endocrinology and Metabolism 2005 90 5684-5691.
13. Frohman L & Bonert V. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Pituitary 2007 10 283-289.
14. Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ & Gagel RF. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. European Journal of Endocrinology 2008 159 517-523.
15. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C & Ørskov H. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Journal of Clinical Endocrinology and Metabolism 2007 92 4598-4601.
16. Drake WM, Berney DM, Kovacs K & Monson JP. Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. European Journal of Endocrinology 2005 153 203-205.
17. Besser GM, Burman P & Daly AE. Predictors and rates of treatment resistant tumor growth in acromegaly. European Journal of Endocrinology 2005 153 187-193.
18. Castinetti F, Morange I, Dufour H, Regis J & Brue T. Radiotherapy and radiosurgery in acromegaly. Pituitary 2009 12 3-10.
19. Bevan JS. Clinical review: the antitumoral effects of somatostatin analogs therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1856-1863.
20. Colao A, Pivonello R, Auriemma RS, Biganti F, Galdiero M, Tortora I, Caranci F, Cirillo S & Lombardi G. Predictors of tumor shrinkage after primary medical treatment with somatostatin analogs in acromegaly: a prospective study in 99 patients. Journal of Clinical Endocrinology and Metabolism 2006 91 2112-2118.
21. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D & Barkan A. Clinical review: a critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 4405-4410.
22. Chakabortty S, Oi S, Yamaguchi M, Tamaki N & Matsumoto S. Growth-hormone producing pituitary adenomas: MR characteristics and pre- and postoperative evaluation. Neurologia Medico-Chirurgica 1993 33 81-85.
23. Dina TS, Feaster SH, Laws ER & Davis DO. MR of the pituitary gland postsurgery: serial MR studies following transsphenoidal resection. American Journal of Neuroradiology 1993 14 763-769.
24. Hald JK, Nahstadt PH, Kollovold T, Bakke SJ & Skalpe IO. MR imaging of pituitary macroadenomas before and after transsphenoidal surgery. Acta Radiologica 1992 33 369-399.
25. Mikhael MA & Ciric IS. MR imaging of pituitary macroadenomas before and after surgical and/or medical treatment. Journal of Computer Assisted Tomography 1988 12 441-445.
26. Steiner E, Knosp E, Herold CJ, Kramer J, Stiglbauer R, Staniszewski K & Imhof H. Pituitary adenomas: findings of postoperative MR images. Radiology 1992 185 521-527.
27. Buchfelder M, Kann PH, Wüster C, Tuschy U, Saller B, Brabant G, Kleindienst A & Nomikos A. Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case-control study. European Journal of Endocrinology 2007 157 149-156.